16 / 35
“
Right drug” also means upfront PDL-1 IHC in
advanced NSCLC
•
For some NSCLC patients IO is truly a life changing treatment.
•
However, durable effects have only been demonstrated in a subset of patients
•
Key next steps are
–
To identify the patients most likely to benefit from IO.
–
To understand mechanisms of resistance
•
Different biomarkers under research: PDL1 IHC, TMB, immune signatures…
–
Currently, PDL1 status is key to select Pembrolizumab upfront!